Patrick Forde, Professor of Thoracic Oncology at Johns Hopkins University, shared a post on X by NEJM (New England Journal of Medicine) about a paper he co-authored with colleagues:
“Visual graphic research summary now out for the CheckMate 816 trial in the New England Journal of Medicine!”
Quoting NEJM’s post:
“In resectable lung cancer, neoadjuvant nivolumab plus chemotherapy improved 5-year overall survival, with no lung cancer deaths reported at 5 years in patients with a pathological complete response. Full CheckMate 816 phase 3 trial results and Research Summary.”
Title: Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
Authors: Patrick M. Forde, Jonathan D. Spicer, Mariano Provencio, Tetsuya Mitsudomi, Mark M. Awad, Changli Wang, Shun Lu, Enriqueta Felip, Scott J. Swanson, Julie R. Brahmer, Keith Kerr, Janis M. Taube, Tudor-Eliade Ciuleanu, Fumihiro Tanaka, Gene B. Saylors, Ke-Neng Chen, Hiroyuki Ito, Moishe Liberman, Claudio Martin, Stephen Broderick, Lily Wang, Junliang Cai, Quyen Duong, Stephanie Meadows-Shropshire, Joseph Fiore, Sumeena Bhatia, Nicolas Girard
You can read the Full Article on NEJM.
More posts featuring Patrick Forde.
